Prime Medicine (NASDAQ: PRME) insider transactions
In the twelve months to 10 November 2026, executives and directors of Prime Medicine reported no open-market sales and no open-market purchases, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 August 2025 | Alphabet Inc. | — | Open-market purchase | +1,500,000 | $3.30 | 3,262,440 | Form 4 |
| 1 August 2025 | Gillis Steven | — | Open-market purchase | +3,030,300 | $3.30 | 6,230,300 | Form 4 |
| 1 August 2025 | ARCH Venture Fund XII, L.P. | — | Open-market purchase | +3,030,300 | $3.30 | 6,230,300 | Form 4 |
| 1 August 2025 | Nelsen Robert | Director | Open-market purchase | +3,030,300 | $3.30 | 6,230,300 | Form 4 |
| 30 June 2025 | Liu David R. | — | Open-market purchase, 10b5-1 plan | +21,000 | $2.52 | 20,240,945 | Form 4 |
| 23 June 2025 | Liu David R. | — | Open-market purchase, 10b5-1 plan | +21,000 | $2.16 | 20,219,945 | Form 4 |
| 16 June 2025 | Liu David R. | — | Open-market purchase, 10b5-1 plan | +21,000 | $1.49 | 20,198,945 | Form 4 |
| 11 June 2025 | Liu David R. | — | Open-market purchase, 10b5-1 plan | +21,000 | $1.60 | 20,177,945 | Form 4 |
| 21 May 2025 | Reine Allan | Chief Executive Officer | Open-market purchase | +125,000 | $1.18 | 125,000 | Form 4 |
| 21 May 2025 | Lee Ann L. | Chief Technical Officer | Open-market purchase | +100,000 | $1.13 | 100,000 | Form 4 |
| 20 May 2025 | Brudnick Richard | Chief Business Officer | Open-market purchase | +20,000 | $1.19 | 20,000 | Form 4 |
| 8 October 2024 | Gottesdiener Keith Michael | See Remarks | Gift | −226,925 | — | 50,241 | Form 4 |
| 8 October 2024 | Gottesdiener Keith Michael | See Remarks | Gift | +226,925 | — | 682,259 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Prime Medicine page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.